Detailed description page of ThPDB2
This page displays user query in tabular form. |
16185 details |
Primary information | |
---|---|
ID | 16185 |
Therapeutic ID | Th1698 |
Protein Name | VPM4001 |
Sequence | NA |
Molecular Weight | NA |
Chemical Formula | NA |
Isoelectric Point | NA |
Hydrophobicity | NA |
Melting point | NA |
Half-life | NA |
Description | VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon- and interleukin-2 (LNCaP/IL-2/IFN-). Interferon- enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells. |
Indication/Disease | Investigated for use/treatment in prostate cancer. |
Pharmacodynamics | NA |
Mechanism of Action | NA |
Toxicity | NA |
Metabolism | NA |
Absorption | NA |
NA | |
Clearance | NA |
Categories | NA |
Patents Number | NA |
Date of Issue | NA |
Date of Expiry | NA |
Drug Interaction | NA |
Target | NA |
Brand Name | NA |
Company | NA |
Brand Description | NA |
Prescribed For | NA |
Chemical Name | NA |
Formulation | NA |
Physical Appearance | NA |
Route of Administration | NA |
Recommended Dosage | NA |
Contraindication | NA |
Side Effects | NA |
Useful Link 1 | Link |
Useful Link 2 | NA |
Remarks | NA |